ABT-239
ABT-239
ABT-239 is a potent and selective histamine H3 receptor antagonist that has been studied for its potential therapeutic effects in various neurological disorders. The compound was developed by Abbott Laboratories and has been the subject of research due to its ability to enhance cognitive function and wakefulness.
Mechanism of Action
ABT-239 functions by blocking the histamine H3 receptor, which is primarily found in the central nervous system. The H3 receptor acts as an autoreceptor and heteroreceptor, modulating the release of various neurotransmitters such as histamine, acetylcholine, norepinephrine, and dopamine. By inhibiting this receptor, ABT-239 increases the release of these neurotransmitters, which can enhance cognitive processes and alertness.
Potential Therapeutic Uses
Research has suggested that ABT-239 may be beneficial in treating conditions such as attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, and schizophrenia. Its ability to improve cognitive performance and memory makes it a candidate for addressing cognitive deficits associated with these disorders.
Cognitive Enhancement
Studies have shown that ABT-239 can improve learning and memory in animal models. This has led to interest in its potential use as a cognitive enhancer in humans, particularly for individuals with cognitive impairments.
Wakefulness Promotion
ABT-239 has also been investigated for its effects on sleep-wake regulation. By increasing the release of neurotransmitters involved in wakefulness, it may help in managing conditions characterized by excessive daytime sleepiness.
Development and Research
Although ABT-239 showed promise in preclinical studies, its development was halted due to concerns about its safety profile. However, the research on ABT-239 has paved the way for the development of other H3 receptor antagonists with improved safety and efficacy.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
